Decentralised Clinical Trials: Balancing Innovation and Integrity
Decentralised clinical trials expand access and reduce patient burden. Learn how sponsors balance innovation in DCT design, data integrity, and regulatory compliance.
Type at least 2 characters to search
Decentralised clinical trials expand access and reduce patient burden. Learn how sponsors balance innovation in DCT design, data integrity, and regulatory compliance.
Dr David Hayes explains why clinical research should be embedded early in cardiac device development and not treated as a late-stage compliance step.
By directly stimulating the visual cortex instead of relying on the retina or optic nerve, ReVision's FDA Breakthrough Device-designated implant could make vision restoration possible for millions of patients who have no existing treatment options.
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
Decentralised clinical trials promise to transform drug development and pharma strategy. The evidence tells a complex story. Here is what’s working and what still needs to be fixed.
Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.
No result found for
Discover innovative solutions and insights from leading pharmaceutical and life sciences companies driving advances in drug development, biotechnology, healthcare, and scientific innovation.